Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

Lene Ryom, Amanda Mocroft, Ole Kirk, Michael J. Ross, Peter Reiss, Christophe A. Fux, Philippe Morlat, Olivier Moranne, Colette Smith, Wafaa El-Sadr, Matthew Law, Jens D. Lundgren

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objectives: Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown. Design: D:A:D participants with at least three estimated glomerular filtration rates (eGFR) after February 2004 were followed until the first of advanced CKD (confirmed eGFR≤30 ml/min,≥3 months apart), ESRD (dialysis ≥3 months/transplantation), 6 months after last visit or February 2012. Methods: Poisson regression was used to assess risk factors for advanced CKD/ESRD including exposure to potential nephrotoxic antiretroviral drugs and antiretroviral drug discontinuation rates according to latest eGFR. Results: Among 35 192 persons contributing 200 119 person years of follow-up (PYFU), 135 (0.4%) developed advanced CKD (n=114)/ESRD (n=21); incidence rate=0.67 [95% confidence interval (CI), 0.56-0.79]/1000 PYFU. Tenofovir (TDF) was particularly frequently discontinued as eGFR declined. After adjustment, those previously exposed but currently off TDF had similar advanced CKD/ESRD rate ratios compared with those unexposed [1.00 (95% CI, 0.66-1.51)], while those currently on TDF had reduced rates [0.23 (95% CI, 0.13-0.41)]. No consistent associations with other antiretroviral drugs were seen. Results were robust after time-lagging antiretroviral drug exposure, stratifying by baseline eGFR, and allowing for competing risks. Other predictors were diabetes, hypertension, baseline eGFR, smoking and current CD4 + cell count. The incidence rate in nonsmokers with baseline eGFR60 and no diabetes or hypertension was 0.16 (95% CI 0.09-0.26)/1000 PYFU. Conclusion: Neither current nor recent antiretroviral drug use predicted advanced CKD/ESRD during 6 years median follow-up in a large, heterogenenous and primarily white cohort. TDF discontinuation rates increased with decreasing eGFR, leaving a selected group still on TDF at lower advanced CKD/ESRD risk. Traditional renal risk factors and current CD4+ cell count were the strongest advanced CKD/ESRD predictors.

Original languageEnglish (US)
Pages (from-to)187-199
Number of pages13
JournalAIDS
Volume28
Issue number2
DOIs
StatePublished - Jan 14 2014
Externally publishedYes

Fingerprint

Chronic Renal Insufficiency
Chronic Kidney Failure
HIV
Glomerular Filtration Rate
Pharmaceutical Preparations
Confidence Intervals
Tenofovir
CD4 Lymphocyte Count
Hypertension
Social Adjustment
Incidence
Renal Dialysis
Transplantation
Smoking
Kidney

Keywords

  • Advanced chronic kidney disease
  • Adverse events
  • Antiretroviral agents
  • End-stage renal disease
  • HIV
  • Nephrotoxicity
  • Tenofovir

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. / Ryom, Lene; Mocroft, Amanda; Kirk, Ole; Ross, Michael J.; Reiss, Peter; Fux, Christophe A.; Morlat, Philippe; Moranne, Olivier; Smith, Colette; El-Sadr, Wafaa; Law, Matthew; Lundgren, Jens D.

In: AIDS, Vol. 28, No. 2, 14.01.2014, p. 187-199.

Research output: Contribution to journalArticle

Ryom, L, Mocroft, A, Kirk, O, Ross, MJ, Reiss, P, Fux, CA, Morlat, P, Moranne, O, Smith, C, El-Sadr, W, Law, M & Lundgren, JD 2014, 'Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons', AIDS, vol. 28, no. 2, pp. 187-199. https://doi.org/10.1097/QAD.0000000000000042
Ryom, Lene ; Mocroft, Amanda ; Kirk, Ole ; Ross, Michael J. ; Reiss, Peter ; Fux, Christophe A. ; Morlat, Philippe ; Moranne, Olivier ; Smith, Colette ; El-Sadr, Wafaa ; Law, Matthew ; Lundgren, Jens D. / Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. In: AIDS. 2014 ; Vol. 28, No. 2. pp. 187-199.
@article{2bea173cd673410485ba0440a3bef740,
title = "Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons",
abstract = "Objectives: Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown. Design: D:A:D participants with at least three estimated glomerular filtration rates (eGFR) after February 2004 were followed until the first of advanced CKD (confirmed eGFR≤30 ml/min,≥3 months apart), ESRD (dialysis ≥3 months/transplantation), 6 months after last visit or February 2012. Methods: Poisson regression was used to assess risk factors for advanced CKD/ESRD including exposure to potential nephrotoxic antiretroviral drugs and antiretroviral drug discontinuation rates according to latest eGFR. Results: Among 35 192 persons contributing 200 119 person years of follow-up (PYFU), 135 (0.4{\%}) developed advanced CKD (n=114)/ESRD (n=21); incidence rate=0.67 [95{\%} confidence interval (CI), 0.56-0.79]/1000 PYFU. Tenofovir (TDF) was particularly frequently discontinued as eGFR declined. After adjustment, those previously exposed but currently off TDF had similar advanced CKD/ESRD rate ratios compared with those unexposed [1.00 (95{\%} CI, 0.66-1.51)], while those currently on TDF had reduced rates [0.23 (95{\%} CI, 0.13-0.41)]. No consistent associations with other antiretroviral drugs were seen. Results were robust after time-lagging antiretroviral drug exposure, stratifying by baseline eGFR, and allowing for competing risks. Other predictors were diabetes, hypertension, baseline eGFR, smoking and current CD4 + cell count. The incidence rate in nonsmokers with baseline eGFR60 and no diabetes or hypertension was 0.16 (95{\%} CI 0.09-0.26)/1000 PYFU. Conclusion: Neither current nor recent antiretroviral drug use predicted advanced CKD/ESRD during 6 years median follow-up in a large, heterogenenous and primarily white cohort. TDF discontinuation rates increased with decreasing eGFR, leaving a selected group still on TDF at lower advanced CKD/ESRD risk. Traditional renal risk factors and current CD4+ cell count were the strongest advanced CKD/ESRD predictors.",
keywords = "Advanced chronic kidney disease, Adverse events, Antiretroviral agents, End-stage renal disease, HIV, Nephrotoxicity, Tenofovir",
author = "Lene Ryom and Amanda Mocroft and Ole Kirk and Ross, {Michael J.} and Peter Reiss and Fux, {Christophe A.} and Philippe Morlat and Olivier Moranne and Colette Smith and Wafaa El-Sadr and Matthew Law and Lundgren, {Jens D.}",
year = "2014",
month = "1",
day = "14",
doi = "10.1097/QAD.0000000000000042",
language = "English (US)",
volume = "28",
pages = "187--199",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

AU - Ryom, Lene

AU - Mocroft, Amanda

AU - Kirk, Ole

AU - Ross, Michael J.

AU - Reiss, Peter

AU - Fux, Christophe A.

AU - Morlat, Philippe

AU - Moranne, Olivier

AU - Smith, Colette

AU - El-Sadr, Wafaa

AU - Law, Matthew

AU - Lundgren, Jens D.

PY - 2014/1/14

Y1 - 2014/1/14

N2 - Objectives: Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown. Design: D:A:D participants with at least three estimated glomerular filtration rates (eGFR) after February 2004 were followed until the first of advanced CKD (confirmed eGFR≤30 ml/min,≥3 months apart), ESRD (dialysis ≥3 months/transplantation), 6 months after last visit or February 2012. Methods: Poisson regression was used to assess risk factors for advanced CKD/ESRD including exposure to potential nephrotoxic antiretroviral drugs and antiretroviral drug discontinuation rates according to latest eGFR. Results: Among 35 192 persons contributing 200 119 person years of follow-up (PYFU), 135 (0.4%) developed advanced CKD (n=114)/ESRD (n=21); incidence rate=0.67 [95% confidence interval (CI), 0.56-0.79]/1000 PYFU. Tenofovir (TDF) was particularly frequently discontinued as eGFR declined. After adjustment, those previously exposed but currently off TDF had similar advanced CKD/ESRD rate ratios compared with those unexposed [1.00 (95% CI, 0.66-1.51)], while those currently on TDF had reduced rates [0.23 (95% CI, 0.13-0.41)]. No consistent associations with other antiretroviral drugs were seen. Results were robust after time-lagging antiretroviral drug exposure, stratifying by baseline eGFR, and allowing for competing risks. Other predictors were diabetes, hypertension, baseline eGFR, smoking and current CD4 + cell count. The incidence rate in nonsmokers with baseline eGFR60 and no diabetes or hypertension was 0.16 (95% CI 0.09-0.26)/1000 PYFU. Conclusion: Neither current nor recent antiretroviral drug use predicted advanced CKD/ESRD during 6 years median follow-up in a large, heterogenenous and primarily white cohort. TDF discontinuation rates increased with decreasing eGFR, leaving a selected group still on TDF at lower advanced CKD/ESRD risk. Traditional renal risk factors and current CD4+ cell count were the strongest advanced CKD/ESRD predictors.

AB - Objectives: Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown. Design: D:A:D participants with at least three estimated glomerular filtration rates (eGFR) after February 2004 were followed until the first of advanced CKD (confirmed eGFR≤30 ml/min,≥3 months apart), ESRD (dialysis ≥3 months/transplantation), 6 months after last visit or February 2012. Methods: Poisson regression was used to assess risk factors for advanced CKD/ESRD including exposure to potential nephrotoxic antiretroviral drugs and antiretroviral drug discontinuation rates according to latest eGFR. Results: Among 35 192 persons contributing 200 119 person years of follow-up (PYFU), 135 (0.4%) developed advanced CKD (n=114)/ESRD (n=21); incidence rate=0.67 [95% confidence interval (CI), 0.56-0.79]/1000 PYFU. Tenofovir (TDF) was particularly frequently discontinued as eGFR declined. After adjustment, those previously exposed but currently off TDF had similar advanced CKD/ESRD rate ratios compared with those unexposed [1.00 (95% CI, 0.66-1.51)], while those currently on TDF had reduced rates [0.23 (95% CI, 0.13-0.41)]. No consistent associations with other antiretroviral drugs were seen. Results were robust after time-lagging antiretroviral drug exposure, stratifying by baseline eGFR, and allowing for competing risks. Other predictors were diabetes, hypertension, baseline eGFR, smoking and current CD4 + cell count. The incidence rate in nonsmokers with baseline eGFR60 and no diabetes or hypertension was 0.16 (95% CI 0.09-0.26)/1000 PYFU. Conclusion: Neither current nor recent antiretroviral drug use predicted advanced CKD/ESRD during 6 years median follow-up in a large, heterogenenous and primarily white cohort. TDF discontinuation rates increased with decreasing eGFR, leaving a selected group still on TDF at lower advanced CKD/ESRD risk. Traditional renal risk factors and current CD4+ cell count were the strongest advanced CKD/ESRD predictors.

KW - Advanced chronic kidney disease

KW - Adverse events

KW - Antiretroviral agents

KW - End-stage renal disease

KW - HIV

KW - Nephrotoxicity

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=84892373117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892373117&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000042

DO - 10.1097/QAD.0000000000000042

M3 - Article

VL - 28

SP - 187

EP - 199

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -